SubHero Banner

Opdivo® (nivolumab) – New indication

February 2, 2017 – The FDA announced the approval of Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Download PDF